MRI-Targeted Prostate Fusion Biopsy: What Are We Missing outside the Target? Implications for Treatment Planning
-
Published:2024-07-22
Issue:7
Volume:31
Page:4133-4140
-
ISSN:1718-7729
-
Container-title:Current Oncology
-
language:en
-
Short-container-title:Current Oncology
Author:
Oderda Marco1ORCID, Dematteis Alessandro1, Calleris Giorgio1, Diamand Romain2, Gatti Marco3, Marra Giancarlo1, Adans-Dester Gilles4, Al Salhi Yazan5, Pastore Antonio5, Faletti Riccardo3, Gontero Paolo1
Affiliation:
1. Division of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy 2. Department of Urology, Jules Bordet Institute—Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, 1070 Brussels, Belgium 3. Division of Radiology, Department of Surgical Sciences, Molinette Hospital, University of Turin, 10126 Torino, Italy 4. Department of Urology, Centre Hospitalier Universitaire Namur-Godinne, UCLouvain, 5530 Yvoir, Belgium 5. Urology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy
Abstract
Introduction: This study aimed to evaluate the added diagnostic value of systematic biopsies (SBx) after magnetic resonance imaging (MRI)-targeted biopsies (TBx) and the presence of prostate cancer (PCa) outside MRI targets, in a prospective, contemporary, multicentric series of fusion biopsy patients. Methods: We collected data on 962 consecutive patients who underwent fusion biopsy between 2022 and 2024. Prostate cancer was considered clinically significant (csPCa) in the case of grade ≥ 2. Median test and Fisher exact chi-square tests were used. To identify predictors of out-field positivity, univariate and multivariable logistic regression analyses were performed. Results: Prostate cancer and csPCa were detected by TBx only in 56% and 50%, respectively, and by SBx only in 55% and 45%, respectively (p < 0.001). Prostate cancer and csPCa were diagnosed by TBx in 100 (10%) and 82 (8%) SBx-negative cases and by SBx in 86 (9%) and 54 (6%) TBx-negative cases (p < 0.001). Tumors outside MRI targets were found in 213 (33%) cases in the same lobe and 208 (32%) in the contralateral lobe, most of them being csPCa. Predictors of out-field contralateral PCa were positive DRE (HR 1.50, p 0.03), PSA density ≥ 0.15 (HR 2.20, p < 0.001), and PI-RADS score 5 (HR 2.04, p 0.01). Conclusions: Both TBx and SBx identify a non-negligible proportion of csPCa when the other modality is negative. SBx after TBx should always be considered given the risk of missing other csPCa foci within the prostate, especially in patients with positive DRE, PSA density ≥ 0.15, and PIRADS 5 lesions.
Reference21 articles.
1. Mottet, N., Cornford, P., van den Bergh, R.C.N., Briers, E., Eberli, D., De Meerleer, G., De Santis, M., Gillessen, S., Grummet, J., and Henry, A.M. (2024, July 01). EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-06-13-141145 n.d. Available online: https://d56bochluxqnz.cloudfront.net/documents/pocket-guidelines/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Pocket-on-Prostate-Cancer-2023.pdf. 2. Prostate Magnetic Resonance Imaging, with or without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis;Drost;Eur. Urol.,2019 3. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): A prospective, multicentre, paired diagnostic study;Puech;Lancet Oncol.,2019 4. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study;Cornel;Eur. Urol.,2019 5. Bourgeno, H.-A., Jabbour, T., Baudewyns, A., Lefebvre, Y., Ferriero, M., Simone, G., Fourcade, A., Fournier, G., Oderda, M., and Gontero, P. (Eur. Urol. Oncol., 2024). The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging–targeted Prostate Biopsy, Eur. Urol. Oncol., in press.
|
|